Trial Profile
Phase 3 double-blinded, placebo-controlled, randomized, multinational study of Avigan (favipiravir) for the prevention of COVID-19
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms PEPCO
- Sponsors Appili Therapeutics
- 17 Jun 2021 According to an Appili Therapeutics media release, the company expects to initiate enrollment in the second half of 2021 following successful completion of the PRESECO study.
- 08 Dec 2020 New trial record
- 24 Nov 2020 According to a Appili Therapeutics media release, The PEPCO and PRESECO studies will be part of the dataset for the recently announced consortium to develop and distribute Avigan tablets globally in COVID-19 indications. The company may expand these trials into other countries severely affected by COVID, including those in Central and South America and the European Union.